These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 22691297

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Triptorelin in the management of prostate cancer.
    Ploussard G, Mongiat-Artus P.
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [Abstract] [Full Text] [Related]

  • 5. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN, Salem AH.
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
    Lundström EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, Strasheim EA, Bigalke MC, Pontin AR, Goedhals L, Steyn DG, Heyns CF, Aldera LA, Mackenzie TM, Purcea D, Grosgurin PY, Porchet HC.
    Clin Drug Investig; 2009 Sep; 29(12):757-65. PubMed ID: 19888782
    [Abstract] [Full Text] [Related]

  • 8. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study.
    Bouchot O, Soret JY, Jacqmin D, Lahlou N, Roger M, Blumberg J.
    Horm Res; 1998 Sep; 50(2):89-93. PubMed ID: 9701702
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
    Østergren PB, Kistorp C, Fode M, Henderson J, Bennedbæk FN, Faber J, Sønksen J.
    J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
    [Abstract] [Full Text] [Related]

  • 12. Triptorelin embonate (6-month formulation).
    Keating GM.
    Drugs; 2010 Feb 12; 70(3):347-53. PubMed ID: 20166771
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K, Akaza H, Naito S, Usami M, Tsukamoto T, Shimazaki J, Kotake T, Yamanaka H, Oohashi Y, Yoshinaka R, Onouchi H, Yokokawa K.
    Hinyokika Kiyo; 2002 Dec 12; 48(12):781-95. PubMed ID: 12613016
    [Abstract] [Full Text] [Related]

  • 17. [Diferelin treatment of primary local and generalized cancer of the prostate].
    Kolesnikov GP, Rusakov IG, Shaplygin LV, Voznesenskiĭ SA, Bystrov AA.
    Urologiia; 2001 Dec 12; (6):17-9. PubMed ID: 11785073
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K, Yamanaka H, Ito K, Yoshinaka R, Uchida S, Yokokawa K.
    Hinyokika Kiyo; 2002 Dec 12; 48(12):771-9. PubMed ID: 12613015
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.